Featured
| Dec 31 | The Biggest Medical Advances of 2024: Transforming Lives read more » |
| Dec 30 | Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis read more » |
| Dec 31 | A Look at 2024’s Patent Expirations and Generic Competition read more » |
| Dec 31 | Pfizer ends work on Sangamo’s hemophilia gene therapy, crushing biotech’s hopes read more » |
| Dec 30 | NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger read more » |
| Dec 30 | CARsgen Announces Positive Topline Results from China GC/GEJ Pivotal Phase II Clinical Trial of Claudin18.2 CAR-T (Satri-cel) read more » |
| Dec 26 | AusperBio Secures $73 Million in Series B Financing to Advance Functional Cure for Chronic Hepatitis B read more » |
| Dec 31 | Heterogeneity, a weak link between constrained dose of AAV and long-term efficacy of gene therapy to muscular dystrophy: A critical review and prospective analysis. read more » |
| Dec 31 | Angiotensin‐converting enzyme 2 modulation of pyroptosis pathway in traumatic brain injury: A potential therapeutic target read more » |
| Dec 30 | Recent developments in translational imaging of in vivo gene therapy outcomes read more » |
| Dec 30 | Autologous transplantation of mitochondria/rAAV IGF-I platforms in human osteoarthritic articular chondrocytes as a novel therapeutic concept for human osteoarthritis read more » |
| Dec 26 | Heat acclimation in mice requires preoptic BDNF neurons and postsynaptic potentiation read more » |
| Dec 26 | Interlaboratory Measurement of Adeno-Associated Virus: Comparative Quantification of Full and Empty Capsids read more » |
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
